Skip to content

A Trial Comparing a Cellulose Dressing to Two Standard of Care Dressings in Treating Split Thickness Donor Sites in Burn and Wound Patients.

A Prospective, Randomized, Controlled Trial Comparing a Cellulose Dressing to Two Standard of Care Dressings in Treating Split Thickness Donor Sites in Burn and Wound Patients.

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05499104
Enrollment
93
Registered
2022-08-12
Start date
2021-07-16
Completion date
2022-02-04
Last updated
2022-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Donor Sites, Pain Management, Wound Drainage, Wound Heal

Brief summary

This is a three arm study, comparing the Novadress, Mepilex Ag, and Xeroform Occlusive dressings for healing, drainage, and pain management. NovaDress is constructed of pure cellulose derived from tree pulp. Mepilex Ag is a antimicrobial foam dressing that absorbs low to moderate exudate and maintains a moist wound environment. Xeroform Occlusive Dressing is a fine-mesh gauze impregnated with a petrolatum blend, 3% bismuth tribromophenate.

Interventions

DEVICENovaDress

NovaDress is constructed of pure cellulose derived from tree pulp. The tree pulp is reconstructed into hydrated sheets wrapped in nonwoven viscose and irradiated.

Mepilex Ag is an antimicrobial foam dressing that absorbs low to moderate exudate and maintains a moist wound environment.

DEVICEXeroform

Xeroform® Occlusive Dressing (XF) is a fine-mesh gauze impregnated with a petrolatum blend, 3% bismuth tribromophenate.

Sponsors

Innovatech Engineering, LLC
CollaboratorUNKNOWN
Joseph M. Still Research Foundation, Inc.
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Is ≥18 years of age. * Has been admitted to the Joseph M. Still Burn Center at Doctors Hospital Augusta or The Advanced Wound Clinic, needing a split-thickness skin graft and will undergo a subsequent donor site harvest. * Subject is able to provide informed consent. * Has a negative urine or serum pregnancy test at screening (if female and has potential for pregnancy) if available or if stated by patient.

Exclusion criteria

* Has a Baux Score of ≥130. * Subject is intubated, unable to state pain levels. * Has active diagnosis of any autoimmune process, cancer, or organ failure that in the opinion of the investigator would prevent the subject from successfully participating in the study, * Has coagulopathy that in the opinion of the investigator, would place subject at an increased risk for bleeding. * Vulnerable subjects who, in the opinion of the Investigator, present with poor skin integrity (i.e. Elderly), is a prisoner, non-English speaking, or is without means of follow-up or return to clinic (i.e. homeless). * Is pregnant, plans to become pregnant, or is actively breastfeeding. * Active illicit drug use. * Is moribund, or in the opinion of the investigator is not expected to survive.

Design outcomes

Primary

MeasureTime frameDescription
Pain and Healing14 daysTo compare and healing (defined as \>95% epithelization) at the study donor sites treated with a cellulose dressing to two standard of care dressings- an antimicrobial foam dressing and a bacteriostatic petrolatum based gauze dressing.

Secondary

MeasureTime frameDescription
Conformability14 daysAbility of dressing to maintain shape measured by staff satisfaction survey
Adherence14 daysAbility of dressing to remain fixed in place measured by staff satisfaction survey
Absorbent ability14 daysAbility of dressing to absorb exudate measured by staff satisfaction survey
Ease of removal14 daysAbility of dressing to be removed in an atraumatic fashion measured by staff satisfaction survey
Cost14 daysAverage cost incurred by the patient for donor site dressings measured by staff satisfaction survey
Management of bloody exudate14 daysAbility of dressing to absorb bloody exudate measured by staff satisfaction survey

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026